Comparison of the Effects of Na+ and K+ Channel Blockers on the Electrophysiological Properties of the Pulmonary Veins in Patients with Atrial Fibrillation

Journal of Arrhythmia

Volumn 26, Issue 4, 2010, Pages 259-266

  Yasuda, Tomoo ^a   Kumagai, Koichiro ^a   Ogawa, Masahiro ^a   Nakashima, Hideko ^a   Zhang, Bo ^a   Miura, Shin Ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Electrophysiology; Nifekalant; Pilsicainide; Pulmonary vein

Indexed keywords

EID: 84872605486     PISSN: 18804276     EISSN: 18832148     Source Type: Journal    
DOI: 10.4020/jhrs.26.259     Document Type: Article

References (30)

1. Haissaguerre M, Jais P, Shah DC, et al: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666
2. Chen SA, Hsieh MH, Tai CT, et al: Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879-1886
3. Pappone C, Rosanio S, Oreto G, et al: Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619-2628
4. Oral H, Knight BP, Ozaydin M, et al: Segmental ostial ablation to isolate the pulmonary veins during atrial fibrillation: feasibility and mechanistic insights. Circulation 2002; 106: 1256-1262
5. Kumagai K, Yasuda T, Tojo H, et al: Role of rapid focal activation in the maintenance of atrial fibrillation originating from the pulmonary veins. Pacing Clin Electrophysiol 2000; 23: 1823-1827
6. Kumagai K, Tojo H, Noguchi H, et al: Effects of the NA+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2004; 15: 1396-1401
7. Kumagai K, Noguchi H, Ogawa M, et al: New approach to pulmonary vein isolation for atrial fibrillation using a multielectrode basket catheter. Circ J 2006; 70(1): 88-93
8. Kanki H, Mitamura H, Takatsuki S, et al: Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. Cardiovasc Drugs Ther 1998; 12: 475-482
9. Kodama I, Ogawa S, Inoue H, et al: Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology). Jpn Circ J 1999; 63: 1-12
10. Yamashita T, Murakawa Y, Sezaki K, et al: Uniqueness of pilsicainide in class Ic antiarrhythmics. Jpn Heart J 1998; 39: 389-397
11. Rensma PL, Allessie MA, Lammers WJ, et al: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395-410
12. Kawase A, Ikeda T, Nakazawa K, et al: Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria. Circulation 2003; 107: 905-910
13. Wijffels MC, Dorland R, Mast F, et al: Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation 2000; 102: 260-267
14. Sakai R, Inoue D, Ishibashi K, et al: Kinetics of frequency-dependent conduction delay by class I antiarrhythmic drugs in human atrium. J Cardiovasc Pharmacol 1995; 25: 953-960
15. Iwasa A, Okumura K, Tabuchi T, et al: Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. Eur J Pharmacol 1998; 356: 31-40
16. Shinagawa K, Mitamura H, Takeshita A, et al: Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. J Am Coll Cardiol 2000; 35: 246-253
17. Atarashi H, Inoue H, Hiejima K, et al: Conversion of recent-onset atrial fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation). The PSTAF Investigators. Am J Cardiol 1996; 78: 694-697
18. Okishige K, Fukunami M, Kumagai K, et al: Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II. Circ J 2006; 70(6): 657-661
19. Kumagai K, Abe H, Hiraki T, et al: Single oral administration of pilsicainide versus infusion of disopyr-amide for termination of paroxysmal atrial fibrillation: a multicenter trial. Pacing Clin Electrophysiol 2000; 23: 1880-1882
20. Jais P, Hocini M, Macle L, et al: Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation. Circulation 2002; 106: 2479-2485
21. Arora R, Verheule S, Scott L, et al: Arrhythmogenic substrate of the pulmonary veins assessed by highresolution optical mapping. Circulation 2003; 107: 1816-1821
22. Kumagai K, Ogawa M, Noguchi H, et al: Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter. J Am Coll Cardiol 2004; 43: 2281-2289
23. Nakaya H, Uemura H: Electropharmacology of nifekalant, a new class III antiarrhythmic drug. Cardiovasc Drug Rev 1998; 16: 133-144
24. Martin DK, Nakaya Y, Wyse KR, et al: Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS 551. Pharmacol Toxicol 1995; 77: 65-70
25. Mori K, Saito T, Masuda Y, Nakaya H: Effects of class III antiarrhythmic drugs on the Na(+)-activated K+ channels in guinea-pig ventricular cells. Br J Pharmacol 1996; 119: 133-141
26. Watanabe H, Watanabe I, Nakai T, et al: Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium. Jpn Circ J 2001; 65 : 1-6.
27. Minami T, Isomoto S, Nakao K, et al: Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2004; 27: 212-217
28. Wang J, Bourne GW, Wang Z, et al: Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Circulation 1993; 88: 1030-1044
29. Verheijck EE, van Ginneken AC, Bourier J, et al: Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. Circ Res 1995 Apr; 76(4): 607-615
30. Wang J, Feng J, Nattel S: Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994; 90: 2032-2040